Saturday 17 October 2026
Export PHAT’s income statement to Excel — free account
Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024. In the quarter to June 2026, revenue grew 88.0%, EPS grew 80.0%, free cash flow grew 96.9% and total debt fell 19.8%, each against the same quarter a year earlier.
6.92
0.58
−7.73%
Follow PHAT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.79 | 4.45 | 6.91 | 5.87 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(470.81) | (58.26) | (241.90) | (61.20) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.76 | 4.42 | 7.42 | 6.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.56) | (9.28) | (7.79) | (4.20) | |
EV/FCF |
(24.41) | (9.25) | (7.78) | (4.20) | |
Quick Ratio |
1.82 | 2.09 | 1.58 | 2.05 | |
Current Ratio |
1.92 | 2.21 | 1.73 | 2.23 | |
Net Debt/EBITDA |
6.09 | 1.19 | (15.85) | (5.02) | |
Debt/Assets |
50.32% | 53.64% | 80.68% | 86.18% | |
Debt/Equity |
(0.48) | (0.49) | (0.48) | (0.49) | |
Asset Turnover |
0.83 | 0.68 | 0.55 | 0.47 | |
Operating CF/Net income |
0.11 | 0.52 | 0.24 | 0.47 | |
Capex/Depreciation |
(0.04) | (0.06) | (0.09) | (0.03) | |
Interest Coverage |
(0.26) | (0.98) | (0.36) | (0.95) | |
Research and Development Expense of Revenue |
10.52% | 13.33% | 13.01% | 14.19% | |
Selling, General and Administrative Expense of Revenue |
74.49% | 92.64% | 84.00% | 104.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.04% | 9.49% | 9.74% | 18.78% | |
Graham Net Nets |
(0.41) | (0.40) | (0.39) | (0.53) | |
Graham Number |
10.88 | 14.00 | 20.34 | 22.24 | |
Earnings Yield |
(11.80%) | (19.08%) | (18.44%) | (32.46%) | |
Free Cash Flow Yield |
(4.06%) | (10.72%) | (13.81%) | (26.09%) | |
Revenue per Share |
0.89 | 0.71 | 0.79 | 0.67 | |
Operating CF per Share |
(0.02) | (0.19) | (0.07) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.19) | (0.07) | (0.19) | |
Cash per Share |
2.18 | 2.20 | 1.78 | 1.84 | |
Shareholders Equity per Share |
(4.11) | (4.11) | (6.01) | (5.76) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.11) | (4.11) | (6.01) | (5.76) | |
Free Cash Flow |
(1.97) | (15.71) | (5.09) | (14.14) | |
Working Capital |
142.14 | 151.53 | 96.93 | 114.66 | |
Capital Expenditures |
(0.04) | (0.06) | (0.09) | (0.03) | |
Net Current Asset Value |
(375.43) | (365.50) | (468.35) | (455.04) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
74.34 | 58.54 | 58.46 | 38.42 | |
Average Payables |
4.68 | 8.99 | 7.75 | 4.10 | |
Average Inventory |
5.57 | 4.84 | 4.36 | 3.36 | |
Average Assets |
288.65 | 299.66 | 318.73 | 313.67 | |
Average Common Equity |
(375.05) | (337.67) | (345.87) | (304.82) |
Columns are period end dates